New Frontiers in Breast Cancer: Updates and Advances in Treatment

Expert oncologists incorporate personal experience with data from the recent ASCO 2022 annual meeting to highlight optimal testing and management strategies in breast cancer.

EP. 1: Optimizing Breast Cancer Management: Molecular Targets and Platforms for Testing

July 27th 2022

Expert oncologists identify molecular targets in breast cancer and review available testing platforms in the current treatment paradigm.

EP. 2: Next-Generation Sequencing Platforms for Late-Stage HR+ Breast Cancer

July 27th 2022

Shared insight on next-generation sequencing platforms, plasma- and tumor-based, for patients with late-stage HR+ breast cancer.

EP. 3: Adjuvant Olaparib in High-Risk gBRCA1/2 Mutated BC: The OlympiA Trial

August 3rd 2022

Comprehensive insight on trial data from OlympiA, which utilized adjuvant olaparib therapy in patients with gBRCA1/2 mutated breast cancer.

EP. 4: Adjuvant Abemaciclib in High-Risk HR+/HER2-, Node+ BC: The monarchE Trial

August 3rd 2022

Focusing on high-risk HR+/HER2- breast cancer, key opinion leaders review data with adjuvant abemaciclib from the monarchE clinical trial.

EP. 5: KEYNOTE-522: Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in TNBC

August 10th 2022

Expert perspectives on the KEYNOTE-522 clinical trial, which utilized adjuvant pembrolizumab following neoadjuvant pembrolizumab plus chemotherapy in TNBC.

EP. 6: Utilizing Brain MRI to Inform Treatment for HER2+ Metastatic Breast Cancer

August 10th 2022

A brief review of the value of using brain MRI to help determine treatment approaches for patients with HER2+ metastatic breast cancer.

EP. 7: DESTINY-Breast03: T-DXd in Previously Treated HER2+ Breast Cancer

August 17th 2022

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

EP. 8: HER2CLIMB: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

August 17th 2022

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

EP. 9: DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer

August 24th 2022

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

EP. 10: TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Breast Cancer

August 24th 2022

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

EP. 11: Audience Q&A: Future Directions in Breast Cancer Care

August 31st 2022

Closing out the discussion on molecular targets and clinical trials in breast cancer, expert oncologists take time to field questions from the live audience.